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Abstract
Background: In recent years it has become evident that nonsteroidal anti-inflammatory drugs, in
particular aspirin represent a potential class of cancer chemotherapeutic agents. Despite the wealth
of knowledge gained from epidemiological, clinical and animal studies, the effectiveness of aspirin
to treat established gastrointestinal cancer has not been determined. The present study examines
the ability of aspirin to treat established polyposis in Min/+ mice.
Methods: Min/+ mice with established polyposis were treated orally once daily from 12–16 weeks
of age with either drug vehicle or aspirin (25 mg/kg). Upon completion of treatment, the number,
location and size of intestinal tumours was determined. Additional variables examined were the
number of apoptotic cells within tumours and COX activity.
Results: Administration of aspirin for 4 weeks to Min/+ mice produce no effect on tumour number
compared to vehicle-treated Min/+ mice (65 ± 8 vs. 63 ± 9, respectively). In addition, aspirin had
no effect on tumour size or location. However, aspirin treatment produced a greater than 2-fold
(p < 0.05) increase in the number of apoptotic positive cells within tumours and significantly
decreased hepatic PGE2 content.
Conclusions: Aspirin was found to have no effect on tumour number and size when administered
to Min/+ mice with established polyposis. The findings in the present study call in to question the
utility of aspirin as a stand-alone treatment for established GI cancer. However, aspirin's ability to
significantly promote apoptosis may render it suitable for use in combinatorial chemotherapy.
Background
Despite continuing decreases in incidence and mortality
rates, cancers of the colon and rectum remain the third
leading cause of cancer deaths in the North America [1,2].
The decline in incidence, and hence mortality, from color-
ectal cancers is most likely attributable to an increase in
recommendations to perform routine screening on aver-
age risk individuals and to improved screening techniques
[2]. In addition, there is ever advancing knowledge into
the pathogenic mechanism of cancer and resulting strides
in the development of more efficacious therapies.
In recent years it has become evident that nonsteroidal
anti-inflammatory drugs (NSAIDs) represent a potential
class of cancer chemotherapeutic agents. The utility of
NSAIDs, in particular aspirin, in the treatment of colon
cancer has stemmed from studies conducted both in ani-
mals [3–11] and humans [12–15]. Evidence from human
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studies has largely come from epidemiological data indi-
cating that aspirin and other NSAIDs can reduce the rela-
tive risk of developing colorectal cancer by approximately
40–50% [13–16]. The utility of NSAIDs in the cancer ther-
apeutics is not limited to prevention strategies. The
NSAID sulindac has been shown to cause regression of
colorectal adenomas of patients with hereditary forms of
polyposis (Familial Adenomatous Polyposis (FAP) and
Gardner's Syndrome) [17–19] and in sporadic colorectal
adenomas [20]. In addition, case reports have demon-
strated that indomethacin and sulindac were effective co-
therapy agents in the treatment of desmoid tumours
[21,22]. Finally, the inclusion either of indomethacin,
naproxen or sulindac in the chemotherapy regiment of
gastric carcinoma patients resulted in a significant in-
crease in survival; 30 months versus 6 months when
NSAIDs included in treatment regime [22].
The anti-neoplastic properties of NSAIDs can be duplicat-
ed in animal models (mainly rodent) of colon cancer. The
two most commonly used are the multiple intestinal neo-
plasia (Min/+) mouse and the chemically (azoxymeth-
ane)-induced rat models. In both models, NSAID
administration has been reported to significantly attenu-
ate tumour number and size when provided either as a
preventive [3–11] or treatment [3,6,11] agent. The Min/+
model has received great favour because it contains a mu-
tation in the Apc gene, which is homologous to the hu-
man adenomatous polyposis coli (APC) gene [23].
Defects in the APC tumour suppressor gene are thought to
play a role in greater than 70% of all colorectal cancers
and is responsible for inherited syndromes of polyposis
(FAP and Gardner's) [24,25]. Furthermore, in humans the
majority of colorectal cancers arise from adenomatous
polyps [26].
Polyposis in the Min/+ mouse differs slightly from the hu-
man condition of FAP. Polyps (multiple) are generally lo-
calized to the small intestine in Min/+ mice, opposed to
the colons of FAP suffers [27]. In Min/+ mice adenoma
formation is thought to occur within the first few weeks of
life, with a full compliment of adenomas being attained
by approximately 9 weeks of age (60–67 days of age)
[6,28]. Following this time, adenoma multiplicity is
thought not to change, however, adenoma size may still
increase [6,28]. Min/+ mice are also normally found to de-
velop anaemia by 60 days of age and possess a shortened
life span of roughly 120 days (17 weeks) [29].
Aspirin most likely represents the best known and fre-
quently purchased NSAID [26]. It is also the NSAID nor-
mally cited in epidemiological studies assessing the
chemopreventive efficacy of NSAIDs [16], but yet the util-
ity of aspirin in the treatment of established colorectal can-
cer has not been determined. We therefore wanted to
determine if aspirin is able to reduce the number and size
of adenomas in Min/+ mice with established polyposis.
Materials and methods
Animals
Min/+ (C57BL/6J-ApcMin) and wild type (C57BL/6J) mice
were purchased from Jackson Laboratories (Bar Harbor,
ME). Mice were housed in a room with a 12 hour light-
dark cycle and had free access to food (LabDiet,® Prolab®
RMH 3500, Purina Mills, Inc., St. Louis, MO) and water
during the entire protocol. All procedures were approved
by the Albany Medical College Institutional Animal Care
and Use Committee (IACUC).
Treatment protocol
Min/+ mice were treated for a period of 28 days either with
vehicle or aspirin (25 mg/kg/day). Dose of aspirin corre-
lates to previous work conducted by Mahmoud et al. [9],
which demonstrated that 0.5 mg of aspirin per day was
chemopreventive in Min/+ mice. Aspirin was initially dis-
solved in dimethyl sulfoxide (DMSO; 5% by final vol-
ume) and then diluted to the desired concentration (5
mg/mL) with 0.5% carboxymethylcellulose (CMC). Both
aspirin and drug vehicle were orally administered via a 22-
gauge feeding needle (Kent Scientific Co., Litchfield, CT)
attached to a 1 cc syringe. Compounds were delivered at a
rate of 5 mL/kg body weight. A diluted concentration was
used to aid in drug solubility and accuracy of drug admin-
istration.
Treatment began at 12 weeks (84 days) of age and con-
cluded at 16 weeks (112 days) of age. Following comple-
tion of the treatment period, mice were euthanized with
sodium pentobarbital (Nembutal®; 50 mg/kg i.m.) and
the entire gastrointestinal (GI) tract was removed. The GI
tract was segregated into stomach, small intestine and co-
lon, and placed into 10% phosphate buffered formalin for
fixation. A portion of liver tissue was also obtained to de-
termine cyclooxygenase (COX) activity.
Assessment of polyp number and size
Following a 24 hour fixation period, the stomach and in-
testines were opened longitudinally and rinsed with phos-
phate buffered saline (PBS, pH 7.4). Tissues were then
pinned flat on wax blocks and covered with trypan blue
(0.4% solution) for 10 minutes and rinsed with PBS to
improve polyp contrast. Polyp numbers were determined
by manual count via use of a dissecting microscope
(Bausch & Lomb, Rochester, NY) by an observer unaware
of the treatment the mice had received. The entire GI tract
for each animal was then photographed using a video
camera (JVC, Wayne, NJ) outfitted with a Navitar Zoom
7000 macro lens (Technical Instruments, San Francisco,
CA). Images were captured and analysed by use of compu-
terised software (Scion Image, Scion Corporation, Freder-BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/19
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ick, MD). Individual polyp diameters were calculated
from their measured areas.
Immunohistochemical detection of apoptosis
Sections of formalin-fixed small intestinal tissues, approx-
imately 15 cm in length, were rolled upon themselves
with the mucosal surface facing outwards. Tissue sections
were then processed and embedded in paraffin using rou-
tine histological techniques. Small intestinal tissue was
sectioned at 4 µm and immobilised on slides.
Apoptotic cells were labelled in situ by use of a commer-
cially available detection kit (TACS 2 TdT DAB kit, Trevi-
gen, Inc., Gaithersburg, MD). Samples were processed
according to the manufacturer's instructions. Briefly, par-
affin wax was removed from slides by heating at 57°C for
20 minutes, followed by two subsequent washes in 100%
Xylene. Slides were then rehydrated by sequential washes
in ethanol (100%, 95% and 70%, 1 × 5 min.), deionized
water (2 × 2 min.) and PBS (1 × 10 min.). Following rehy-
dration, tissue was proteolytically treated (Proteinase K,
20 µg/mL) for 15 minutes. Endogenous peroxidase activ-
ity was quenched by immersing slides in a 2% hydrogen
peroxide (H2O2) solution. Excess peroxide solution was
removed by tapping and slides were then immediately
submersed in labelling buffer (50 mM Tris, pH 7.5; 5 mM
MgCl2; 0.06 mM 2-Mercaptoethanesulfonic Acid; 0.05
mg/mL BSA) for 2 minutes. Slides were removed from la-
belling buffer and excess buffer surrounding the tissue was
wiped away. Samples were covered with labelling reaction
mixture (50 mM Tris, pH 7.5; 5 mM MgCl2; 0.06 mM 2-
Mercaptoethanesulfonic Acid; 0.05 mg/mL BSA; 1 mM
CoCl2; 0.008 mM TdT dNTP mix; 300 U/mL TdT) and in-
cubated for 60 minutes in a humidified chamber (37°C).
The labelling reaction was terminated by transferring the
slides to 50 mL of stop buffer (10 mM EDTA, pH 8.0) for
5 minutes. Excess stop buffer was removed by washing the
slide once in 50 mL of PBS for 2 minutes.
Detection of labelled cells was carried out via the conver-
sion of diaminobenzidine (DAB) by streptavidin-horse-
radish peroxidase (strep-HRP). Labelled samples were
covered with 100 µL strep-HRP solution and incubated
for 10 minutes. Excess strep-HRP was removed by tapping
prior to washing the slide twice in 50 mL of PBS. Slides
were placed into 50 mL of DAB solution (0.5 mg/mL DAB
and 0.03% H2O2 in PBS) for 5 to 10 minutes. Slides were
briefly rinsed twice with deionized water, prior to counter-
staining with methyl green.
Apoptotic cells were counted manually by an observer un-
aware of the treatment regime and were normalised based
on polyp area. Polyp area was determined from captured
images (Nikon, Labophot-2 microscope fitted with a JVC
video camera) using the same computerised software stat-
ed above.
Assessment of cyclooxygenase activity
Cyclooxygenase activity was assessed ex vivo in hepatic tis-
sue following a previously described method [30]. Briefly,
mice were euthanized 3 hours following the final dose of
vehicle or aspirin and a sample of liver tissue (~100 mg)
was obtained. The samples were then placed into micro-
centrifuge tubes containing 1 mL of sodium phosphate
buffer (10 mmol/L, pH 7.4) and finely minced with scis-
sors for 15 seconds. Samples were then incubated for 20
minutes at 37°C in a shaking water bath. Following the in-
cubation period, samples were centrifuged at 9 000 × g for
30 seconds and the supernatants collected. Supernatants
were flash frozen in liquid nitrogen and stored at -80°C
for subsequent determination of prostaglandin E2 (PGE2)
content. PGE2 concentrations were determined using a
commercially available ELISA assay (Cayman Chemical
Company, Ann Arbor, MI).
Materials
Aspirin (acetylsalicylic acid), carboxymethylcellulose,
dimethyl sulfoxide and hydrogen peroxide were obtained
from Sigma Chemical Co. (St. Louis, MO). Histology sup-
plies and reagents were purchased from Fisher Scientific
(Springfield, NJ).
Statistical analysis
All data are expressed as the mean ± SEM. Comparison
among groups of data were made using either an unpaired
Student's t test or one-way analysis of variance (ANOVA),
followed by a Bonferroni's post test. Differences between
groups were considered significant with a p value of less
than 0.05.
Results
Polyp number and size
Sixteen week old Min/+ mice possessed approximately 63
± 9 polyps (n = 13) within their small and large intestine,
combined. Approximately 97% of the polyps present were
located in the small intestine (table 1). Once daily oral ad-
ministration of aspirin (25 mg/kg) for four weeks had no
effect on the number of polyps in the intestinal tract of
Min/+ mice. Aspirin-treated mice contained 62 ± 8 small
intestinal polyps and 2.5 ± 0.4 large intestinal polyps (ta-
ble 1). Concurrent with the above findings, no significant
differences were seen in total adenoma area or average ad-
enoma size. Adenomas in the small intestine had an aver-
age diameter of 1.64 ± 0.22 mm and 1.73 ± 0.14 mm for
vehicle- and aspirin-treated Min/+ mice, respectively. Sim-
ilar findings were seen within large intestine (table 1).
Furthermore, no changes were seen in the distribution of
adenomas when classified according to diameter (figure
1). Small intestinal adenomas were less than 4 mm in di-BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/19
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ameter, with the approximately 75% being 1–3 mm in di-
ameter. Large intestinal adenomas as large as 5–6 mm in
diameter were occasionally seen. Aspirin treatment had
no effect on adenoma size distribution and both profiles
were essentially identical to those of the vehicle-treated
group (figure 1).
Cyclooxygenase activity and apoptosis
Vehicle-treated Min/+ mice displayed a 2-fold increase in
their capacity to generate PGE2 when compared to wild
type mice (figure 2). Once daily aspirin (25 mg/kg p.o.)
administration to Min/+ mice caused a significant reduc-
tion in the ability of liver to generate PGE2 compared to
vehicle-treated Min/+ mice (figure 2). PGE2 levels (3.8 ±
1.0 pg/mg tissue) in the aspirin-treated mice were compa-
rable to those seen in wild type mice.
Aspirin administration also resulted in a significant in-
crease in the number of apoptotic cells found in small in-
testinal adenomas (figure 3). Vehicle-treated Min/+ mice
contained 32.2 ± 5.6 apoptotic cells per area (mm2) of ad-
enoma. The number of apoptotic cells per adenoma area
was twice (67.6 ± 16.7 cells per mm2; p = 0.05) as great in
the aspirin-treated group.
Overall welfare
The quality of life of the Min/+ mice, as assessed by change
in body weight, hematocrit level and overall survival, was
not altered in the aspirin-treated group compared to the
vehicle-treated group (table 2). Wild type animals treated
with vehicle weighed initially 23.6 ± 1.6 g and gained ap-
proximately 2.9 ± 1.9 g over the 4-week period. Vehicle-
and aspirin-treated Min/+ mice initially weighed 24.6 ±
1.1 g and 24.0 ± 1.1 g, respectively. Both Min/+ groups
failed to gain weight, rather a modest decrease in body
weight was noted over the study period (-0.9 ± 1.4 g and -
0.1 ± 1.1 g, respectively). Both the vehicle- and aspirin-
treated groups were found to be anemic based upon he-
matocrit values (table 2). Anaemia is characteristic of the
model [29]. Both treatment groups displayed hematocrit
levels 25–30% lower than expected values. Aspirin treat-
ment did not improve or worsen the anaemia (table 2).
Wild type (C57BL/6J, background strain of Min/+ mice)
are referenced to have hematocrit levels of 44 ± 0.4 %
[31].
Survival rate of the Min/+ mice was greater than 95%. One
animal had to be sacrificed prior (2 days) to the comple-
tion of the study and was in the vehicle treatment group
(table 2). Post-mortem examination revealed a total of 87
polyps (82 small and 5 large intestinal). Data obtained
from this animal was not included in the analysis. In ad-
dition, one animal was found to possess no small or large
intestinal polyps. The animal had been treated with a full
regiment of aspirin, however, it was assumed not to pos-
sess the Min/+ genotype and was therefore not included in
data analysis. A wild type genotype was assumed, since no
existing data suggests or indicates that aspirin is able to
cause complete elimination of adenomas in this model.
The animal also possessed a normal hematocrit value of
44% [31].
Discussion
The American Cancer Society has indicated that cancer in-
cidence rates are on the decline, however, they estimate
that greater than 1.2 million new cases will be diagnosed
this year [1]. Of these new cases, it is expected that color-
ectal cancers will comprise approximately 10–11% [1].
With staggering numbers as these, it is not surprising that
chemoprevention has been proposed as a viable strategy
to fight cancer. Among the leading therapeutic agents in
colorectal cancer prevention are NSAIDs, especially aspi-
rin. Epidemiological studies have indicated that the fre-
quent, long term use of aspirin could reduce the relative
risk of developing colorectal cancer by 40–50% [13–
15,32]. Despite the wealth of information regarding the
Figure 1
Size distribution of adenomas in the small (panel A) and large
(panel B) intestines of Min/+ mice treated once daily with
aspirin over a period of four weeks. Adenoma sizes were
determined from captured images and categorised based on
diameter (mm). Data are presented as the percent of total
polyps.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/19
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chemopreventive ability of aspirin, information to indi-
cate aspirin's utility in a therapeutic modality is lacking.
To date no studies or case reports have examined the use
of aspirin in the treatment of FAP, although various clini-
cal trials are under way [33]. In accordance with the above
data, studies conducted in animals have always employed
a prevention strategy as well [4,7,9]. To our knowledge,
this is the first study to examine the therapeutic potential
of aspirin in a rodent model of colon carcinogenesis, in
particular, the Min/+ murine model of polyposis. The
study revealed that treatment of Min/+ mice with estab-
lished polyposis with aspirin for 4 weeks produce no ap-
preciable therapeutic effect.
While the evaluation of aspirin in the Min/+ model utilis-
ing a therapeutic regime is lacking, other NSAIDs (sulin-
dac, flurbiprofen, piroxicam and celecoxib) have been
shown to significantly reduce polyp numbers when ad-
ministered using similar protocols [6,11,34,35]. In addi-
tion, three recent reports have demonstrated a lack of
effect of aspirin as a chemopreventive agent in Min/+ mice
[36–38]. Combined, these studies indicate that the Min/+
model is responsive to NSAIDs other than aspirin when
provided as a treatment. They also raise into question the
efficacy of aspirin as a chemotherapeutic for colon cancer,
and perhaps more specifically, familial adenomatous
polyposis.
With the exemplary track record of NSAIDs in this model
of colon cancer, why was a lack of effect seen in this mod-
el? Was it a consequence of the dose of aspirin and/or du-
ration of treatment used? In the current study, mice
received approximately 500 µg of aspirin per day. This
amount of aspirin was found by Mahmoud et al.[9] to be
sufficient (significant) to reduce both polyp number and
intestinal prostaglandin (PGE2) content by greater than
45% when provided from 5–6 weeks of age to 16 weeks of
age (i.e., chemopreventive regime). Barnes and Lee [7]
have also suggested that the maximal tumour suppression
for aspirin may be in the 50% range. The above authors
followed a similar protocol to Mahmoud et al. [9], but
employed far greater doses of aspirin (45 and 90 mg/kg/
day) and reported no dose-response relationship and a
maximal suppression of 55% [7]. Furthermore, in the rat
model of azoxymethane-induced colon carcinogenesis,
aspirin has also only been found to inhibit aberrant crypt
foci and tumour development by no more than 65%
[4,39]. Coincidentally, epidemiological data also report
reductions in the 40–50% range [13–15,32]. However,
whether this can be used as an argument to support the
notion that aspirin is only able to suppress tumour forma-
tion by 50% is difficult to extrapolate because two differ-
ent end points are being examined (i.e., relative risk versus
tumour number).
Finally, as indicated earlier, other studies have demon-
strated that doses of NSAIDs other than aspirin which
were found to be chemopreventive were able to produce
similar reductions in polyp numbers when used in a treat-
ment regime [6,11,34,35]. Chiu et al.[6] demonstrated
that Min/+ mice at approximately 11 weeks of age pos-
sessed roughly 35–40 polyps and that treatment (starting
at 11 weeks of age) for as little as 4 days with sulindac pro-
duced a 75% reduction in polyp number. Similarly, Rit-
land and Gendler [34] reported that administration of
piroxicam (200 ppm in diet) to 10–13 week old Min/+
mice for 6 or more days resulted in maximal tumour
number suppression (>90%). Finally, R-flurbiprofen (10
mg/kg/day) orally administered to Min/+ for 42 days start-
ing at 10 weeks of age was also able to decrease tumour
number by greater than 58% [11].
Various studies have reported increased levels of prostag-
landins and COX-2 expression in colorectal adenomas
and adenocarcinomas obtained both from animals
[40,41] and humans [42–44]. These findings have lead to
Table 1: Effect of Aspirin Administration on Polyp Number and Area in Min/+ Mice.
Vehicle-Treated (n = 13) Aspirin-Treated (n = 11)
Small Large Total Small Large Total
Polyp Number 61 ± 9 1.9 ± 0.4 63 ± 9 62 ± 82 . 5  ± 0.4 65 ± 8
Polyp Area (mm2) 183 ± 70 8.7 ± 3.7 192 ± 73 159 ± 44 15.2 ± 5.5 174 ± 47
Polyp Diameter 
(mm)
1.6 ± 0.2 1.8 ± 0.5 NA 1.7 ± 0.1 2.4 ± 0.5 NA
Min/+ Mice were treated orally with either vehicle or aspirin (25 mg/kg) once daily for 28 days, commencing at 12 weeks of age. Data are expressed 
as the mean ± SEM. Groups of data were compared using an unpaired t test. Analysis revealed no statistically significant difference between the 
treatment groups. NA = Not ApplicableBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/19
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the implication that COX-2 plays an important role in in-
testinal neoplasia and that the anti-neoplastic effects of
NSAIDs are attributable to their ability to inhibit COX-2.
In light of this information, the mechanism by which as-
pirin and other NSAIDs inhibit colorectal cancer progres-
sion has not been fully elucidated and cannot simply be
equated to the suppression of COX-2 activity. Shiff and
Rigas [45] indicate that NSAIDs may to affect colorectal
cancer development via one or more of the following four
areas: (1) COX-mediated carcinogen activation, (2) cell
proliferation, (3) apoptosis and (4) immune surveillance.
Within these potential mechanisms exists the possibility
for both COX-dependent and -independent mechanisms.
In the current study we also examined COX-activity and
apoptosis. The treatment regime employed was sufficient
to attenuate COX activity by 75% and increased the
number of apoptotic bodies within tumours by greater
than 2-fold. Similar findings were reported by Mahmoud
et al. [9] using an equivalent dose of aspirin in a preven-
tion strategy. These authors demonstrated a >50% reduc-
tion in small intestinal tumour number and PGE2 content
and a >4-fold increase in apoptosis. Contrary to the simi-
larities seen in COX-inhibition and increased apoptosis,
the present study saw no effect on tumour number or size.
The discordant effect seen between the current study and
that of Mahmoud et al. [9] are difficult to explain. The du-
ration and timing of treatment (i.e., prevention vs. treat-
ment) would seem the most likely explanation. This
possibility has also been eluded in epidemiological stud-
ies. The Physicians' Health Study found no significant re-
duction in the relative risk of developing colorectal cancer
in individuals consuming 325 mg of aspirin every other
day for 5 years [46]. The Nurses' Health Study reported
that a significant decrease in risk was only seen in women
who took aspirin on a regular basis for 10 or more years
[13]. Whether this simple explanation accounts for the
difference in results reported here and by Mahmoud et al.
[9] does not seem likely. As stated earlier, three previous
studies employing prevention strategies and higher doses
of aspirin also found no effect on tumour burden [36–
38]. Perhaps a similar discordant effect will appear in hu-
man studies as results are released from the currently on-
going clinical trials [33]. If such a situation does arise, it
could indicate that aspirin might not be the NSAID of
choice for colorectal cancer therapy. In contrast, to date no
conflicting data have been published regarding the use of
sulindac. Sulindac has been shown to be efficacious both
in rodent models of FAP and in human FAP patients.
Although no change was seen in tumour number or size,
the significant increase seen in apoptosis might imply that
aspirin could still hold utility in treating colorectal cancer.
The present study would suggest that aspirin has little or
no use as a stand-alone therapy, but could present a viable
option in combination chemotherapy. Recent reports by
Torrance et al.[47] and Mann et al.[48] demonstrate that
combinatorial therapy comprised of a COX inhibitor and
Figure 2
Effect of aspirin on cyclooxygenase (COX) activity in Min/+
mice. COX activity was determined by measuring the ability
of hepatic tissue to synthesise prostaglandin E2 (PGE2) ex
vivo. Hepatic tissue was obtained 3 hours following the final
dose of either vehicle (n = 13) or aspirin (25 mg/kg p.o., n =
11). A separate group of wild type mice (n = 6) were treated
with vehicle once daily for 4 weeks to establish normal
capacity of liver tissue to synthesise PGE2. Data are
expressed as the mean ± SEM. * p < 0.05 versus wild type. δ
p < 0.05 versus vehicle-treated Min/+ mice. Statistical analysis
conducted using a one-way analysis of variance with a Bon-
ferroni post test.
Figure 3
Assessment of apoptosis in small intestinal adenomas of vehi-
cle- and aspirin-treated Min/+ mice. Apoptosis was detected
in situ via the TUNEL principle. An average of 4 adenomas
were counted per animal. Data are depicted as the number
of apoptotic cells per adenoma area (mm2). * p = 0.05 versus
vehicle-treated Min/+ mice.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/19
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growth factor receptor inhibitors resulted in synergistic
anti-tumour activity. In fact, the study conducted by Tor-
rance and colleagues [47] demonstrated that doses of
sulindac (5 mg/kg) found to be ineffective as stand-alone
chemotherapy in the Min/+ model became extremely po-
tent when combined with an epidermal growth factor re-
ceptor kinase inhibitor. The combination therapy was
able to completely abolish all macroscopically visible tu-
mours in 47% of the animals treated [47]. This could
prove to be very advantageous since it may allow for lower
doses of NSAIDs to be used, thereby limiting the adverse
effects associated with long term NSAID use. Pursuing fu-
ture research into the combinatorial chemopreventive/
chemotherapeutic potential of aspirin may be of greater
value than trying to account for the discordant effect.
Conclusions
Despite abundant evidence from epidemiological, clinical
and animal studies regarding the potential utility of aspi-
rin as a chemotherapeutic agent for colorectal cancer, the
current study found no change in tumour burden in the
extensively used Min/+ murine model of colon cancer.
The findings that aspirin was still able to significantly in-
crease the number of apoptotic cells within tumours and
lower prostaglandin levels suggests that it may be better
suited to combinatorial therapy, but its utility as a stand-
alone modality in established GI cancer is questionable.
Promising results have already been attained in animal
models using COX inhibitors as co-therapies in the treat-
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